Louis M. Aledort, MD, Receives Lifetime Achievement Award for Blood Disorder Research
Louis M. Aledort, MD is the recipient of the prestigious Lifetime Achievement Award from the Hemophilia and Thrombosis Research Society (HTRS).
Louis M. Aledort, MD, The Mary Weinfeld Professor of Clinical Research in Hemophilia at Mount Sinai School of Medicine, is the recipient of the prestigious Lifetime Achievement Award from the Hemophilia and Thrombosis Research Society (HTRS). Dr. Aledort was given the award in recognition of his distinguished career and outstanding contributions to the field of blood disorders. He received the award at the HRTS and North American Specialized Coagulation Laboratory Association (NASCOLA) Scientific Symposium on Friday, April 16, 2010 in Chicago, Illinois.
"In addition to being a renowned researcher in blood disorders, Dr. Aledort is a tireless advocate for the advancement of his peers, young physicians, and investigators," said Cindy Leissinger, MD, Professor of Medicine, Pediatrics, and Pathology, and Chief of the Section of Hematology & Medical Oncology, Tulane University School of Medicine, who nominated Dr. Aledort. "There is no one more deserving of this award."
A pioneer in the field of coagulation disorders, Dr. Aledort has participated in many seminal projects that have advanced scientific standards in research and patient care. His primary focus is surrounding the safety and efficacy of bleeding disorder treatments, idiopathic thrombocytopenic purpura—a blood disorder where the immune system destroys platelets—and bleeding related to anticoagulant therapy. He has been a leader in the design and implementation of several groundbreaking collaborative study groups, including the U.S. Hemophilia Study Group, the Transfusion Safety Study, and the Orthopedic Outcome Study. He has authored more than 400 peer-reviewed articles in prominent journals, including Haemophilia, Journal of Thrombosis and Haemostasis
"What stands out to many of his colleagues and students is Dr. Aledort's commitment to education and collaborative research," continued Dr. Leissinger. “He provides opportunities for partnership on projects of scientific interest and importance, while fostering and encouraging rigorous academic debate. His counsel has had far-reaching effects and shaped the professional hemophilia community today."
Beyond his commitment to his own research and mentorship of his peers, Dr. Aledort is involved in several professional organizations, including the American Society of Hematology, the International Society of Hematology, and the American College of Physicians, for whom he is a Master. He is the editor of numerous medical journals, has held nearly 50 major positions at governmental, non-profit, and educational organizations, and served on several academic advisory committees.
"I am honored to be recognized by my peers with this prestigious award," said Dr. Aledort. "Research and patient care in anticoagulation disorders has come a long way over the years, and I look forward to seeing the advances that my colleagues make in the years to come."
Dr. Aledort earned his medical degree at the Albert Einstein College of Medicine. He continued his studies as a resident at the University of Virginia and Strong Memorial Hospital in Rochester, NY, where he also had a Hematology Fellowship. From Rochester, Dr. Aledort joined Mount Sinai, where he has remained for 44 years.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses The Mount Sinai Hospital and Mount Sinai School of Medicine. The Mount Sinai Hospital is one of the nation’s oldest, largest and most-respected voluntary hospitals. Founded in 1852, Mount Sinai today is a 1,171-bed tertiary-care teaching facility that is internationally acclaimed for excellence in clinical care. Last year, nearly 60,000 people were treated at Mount Sinai as inpatients, and there were nearly 450,000 outpatient visits to the Medical Center.
Mount Sinai School of Medicine is internationally recognized as a leader in groundbreaking clinical and basic science research, as well as having an innovative approach to medical education. With a faculty of more than 3,400 in 38 clinical and basic science departments and centers, Mount Sinai ranks among the top 20 medical schools in receipt of National Institute of Health (NIH) grants. For more information, please visit www.mountsinai.org.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.